Literature DB >> 24395807

Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis.

Hayato Nakagawa1, Yohko Hikiba, Yoshihiro Hirata, Joan Font-Burgada, Kei Sakamoto, Yoku Hayakawa, Koji Taniguchi, Atsushi Umemura, Hiroto Kinoshita, Kosuke Sakitani, Yuji Nishikawa, Kenji Hirano, Tsuneo Ikenoue, Hideaki Ijichi, Debanjan Dhar, Wataru Shibata, Masao Akanuma, Kazuhiko Koike, Michael Karin, Shin Maeda.   

Abstract

E-cadherin is an important adhesion molecule whose loss is associated with progression and poor prognosis of liver cancer. However, it is unclear whether the loss of E-cadherin is a real culprit or a bystander in liver cancer progression. In addition, the precise role of E-cadherin in maintaining liver homeostasis is also still unknown, especially in vivo. Here we demonstrate that liver-specific E-cadherin knockout mice develop spontaneous periportal inflammation via an impaired intrahepatic biliary network, as well as periductal fibrosis, which resembles primary sclerosing cholangitis. Inducible gene knockout studies identified E-cadherin loss in biliary epithelial cells as a causal factor of cholangitis induction. Furthermore, a few of the E-cadherin knockout mice developed spontaneous liver cancer. When knockout of E-cadherin is combined with Ras activation or chemical carcinogen administration, E-cadherin knockout mice display markedly accelerated carcinogenesis and an invasive phenotype associated with epithelial-mesenchymal transition, up-regulation of stem cell markers, and elevated ERK activation. Also in human hepatocellular carcinoma, E-cadherin loss correlates with increased expression of mesenchymal and stem cell markers, and silencing of E-cadherin in hepatocellular carcinoma cell lines causes epithelial-mesenchymal transition and increased invasiveness, suggesting that E-cadherin loss can be a causal factor of these phenotypes. Thus, E-cadherin plays critical roles in maintaining homeostasis and suppressing carcinogenesis in the liver.

Entities:  

Keywords:  cholangiocellular carcinoma; liver progenitor cell; mixed type tumor

Mesh:

Substances:

Year:  2014        PMID: 24395807      PMCID: PMC3903249          DOI: 10.1073/pnas.1322731111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma.

Authors:  T Osada; M Sakamoto; Y Ino; A Iwamatsu; Y Matsuno; T Muto; S Hirohashi
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

2.  Cre-mediated somatic site-specific recombination in mice.

Authors:  K Akagi; V Sandig; M Vooijs; M Van der Valk; M Giovannini; M Strauss; A Berns
Journal:  Nucleic Acids Res       Date:  1997-05-01       Impact factor: 16.971

3.  Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas.

Authors:  T Matsumura; R Makino; K Mitamura
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

4.  Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas.

Authors:  A Ihara; H Koizumi; R Hashizume; T Uchikoshi
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  E-cadherin is a survival factor for the lactating mouse mammary gland.

Authors:  Oréda Boussadia; Stefanie Kutsch; Andreas Hierholzer; Véronique Delmas; Rolf Kemler
Journal:  Mech Dev       Date:  2002-07       Impact factor: 1.882

6.  E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

Authors:  Xiaolan Qian; Tatiana Karpova; Allan M Sheppard; James McNally; Douglas R Lowy
Journal:  EMBO J       Date:  2004-04-01       Impact factor: 11.598

7.  E-cadherin null mutant embryos fail to form a trophectoderm epithelium.

Authors:  L Larue; M Ohsugi; J Hirchenhain; R Kemler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

8.  Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma.

Authors:  Sun Lee; Woo Ho Kim; Hwoon-Yong Jung; Moon Ho Yang; Gyeong Hoon Kang
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

9.  Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.

Authors:  Yu Wei; Jeanne Tran Van Nhieu; Sylvie Prigent; Petcharin Srivatanakul; Pierre Tiollais; Marie-Annick Buendia
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation.

Authors:  S Orsulic; O Huber; H Aberle; S Arnold; R Kemler
Journal:  J Cell Sci       Date:  1999-04       Impact factor: 5.285

View more
  48 in total

1.  Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer.

Authors:  Joan Font-Burgada; Shabnam Shalapour; Suvasini Ramaswamy; Brian Hsueh; David Rossell; Atsushi Umemura; Koji Taniguchi; Hayato Nakagawa; Mark A Valasek; Li Ye; Janel L Kopp; Maike Sander; Hannah Carter; Karl Deisseroth; Inder M Verma; Michael Karin
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

2.  Intestinal E-cadherin Deficiency Aggravates Dextran Sodium Sulfate-Induced Colitis.

Authors:  Jessica I Grill; Jens Neumann; Felix Hiltwein; Frank T Kolligs; Marlon R Schneider
Journal:  Dig Dis Sci       Date:  2015-01-30       Impact factor: 3.199

3.  Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10.

Authors:  Aditya Ambade; Abhishek Satishchandran; Banishree Saha; Benedek Gyongyosi; Patrick Lowe; Karen Kodys; Donna Catalano; Gyongyi Szabo
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

4.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Kenichiro Enooku; Yotaro Kudo; Yuki Hayata; Takuma Nakatsuka; Yasuo Tanaka; Ryosuke Tateishi; Yohko Hikiba; Kento Misumi; Mariko Tanaka; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Junichi Arita; Kiyoshi Hasegawa; Hadassa Hirschfield; Yujin Hoshida; Yoshihiro Hirata; Motoyuki Otsuka; Keisuke Tateishi; Kazuhiko Koike
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

5.  Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.

Authors:  T Nakatsuka; K Tateishi; Y Kudo; K Yamamoto; H Nakagawa; H Fujiwara; R Takahashi; K Miyabayashi; Y Asaoka; Y Tanaka; H Ijichi; Y Hirata; M Otsuka; M Kato; J Sakai; M Tachibana; H Aburatani; Y Shinkai; K Koike
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

6.  Expression of E-cadherin in oral lichen planus.

Authors:  Yong DU; Haobo Li
Journal:  Exp Ther Med       Date:  2015-07-23       Impact factor: 2.447

Review 7.  From a common progenitor to distinct liver epithelial phenotypes.

Authors:  Anne Müsch
Journal:  Curr Opin Cell Biol       Date:  2018-03-02       Impact factor: 8.382

8.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 9.  Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Peter Fickert
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

10.  Prognostic significance of reduced immunohistochemical expression of E-cadherin in endometrial cancer-results of a meta-analysis.

Authors:  Xing Zheng; Xue-Lian Du; Tao Jiang
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.